Navigation Links
Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Date:10/30/2007

KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers will present 68 data presentations involving Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy, a current standard of care in the treatment of chronic hepatitis C, at the 58th American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Nov. 2-6.

Among these are several studies discussing the predictability of response with PEGINTRON and REBETOL and assessing how results at important treatment milestones early in the course of therapy can help physicians and patients make informed treatment decisions.

Researchers will present the final results from the POWeR (Peginterferon alfa-2b Prospective Optimal Weight-based Dosing Response) program, a large observational study involving nearly 2,000 patients conducted at academic and community clinics in Canada between 2002 and 2006. In the study, PEGINTRON and REBETOL combination therapy achieved consistent sustained virologic response (SVR) rates across patient weights and consistently low relapse rates in a "real-life" treatment setting.

Investigators also will present new data on the investigational use of low-dose PEGINTRON as maintenance therapy in chronic hepatitis C nonresponder patients with fibrosis or cirrhosis. The goal of maintenance therapy in this very hard-to-treat patient population is to prevent or delay the progression of liver disease.

Hepatitis C is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States and 200 million people worldwide.

For program information, please visit the American Association of Liver Disease Web site at http://www.aasld.org.

Key PEGINTRON Presentations:

Predictability of Response

Predictability of Response:
'/>"/>

SOURCE Schering-Plough
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
9. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014 /PRNewswire/ ... post-launch in the United States ... have prescribed GlaxoSmithKline,s BRAF inhibitor Tafinlar for ... 49 percent who have prescribed GlaxoSmithKline,s MEK inhibitor ... the highest percentage (42 percent and 43 percent, ...
(Date:9/18/2014)... 18, 2014  Iliad Neurosciences, Inc., a company focused ... treating Autism Spectrum Disorders (ASD) announced today that it ... Research Foundation for The State University of New York. ... new biomarker to identify an abnormality in folate transport ... biomarker is expected to be available for research use ...
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014  Decision ... launched anti-vascular endothelial growth factor (VEGF) agent for wet ... and Medicare Advantage plans as Genentech,s Lucentis, which is ... although surveyed managed care organization (MCO) directors do not ... Eylea is slightly more likely than Lucentis to be ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 Memorial ... made history this week by performing the first ever, ... UNOS (United Network for Organ Sharing) approval to launch ... one of only two programs in South Florida. ... Dr. Enrique Gongora, Medical Director of the ...
(Date:9/18/2014)... -- Older people become more physically vulnerable during bereavement, ... stress hormones during bereavement changes with age, British researchers ... are more likely to have weakened immune systems and ... weeks and months after loss, we can suffer from ... of white blood cell and as such are essential ...
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... -- Daily supplements of selenium or vitamin E don,t ... cataracts among men, a new study indicates. Previous ... help prevent cataracts. To investigate this further, William Christen, ... in Boston, and his colleagues examined data from a ... trial was initially designed to study prevention of prostate ...
(Date:9/18/2014)... Thousands of college and high school ... fundraising impact on 127 member Children’s Miracle Network ... Dance Marathon Day will officially kick off a school ... raised by college and high school students funding vital ... Dance Marathon campus programs help provide medical equipment, treatment ...
Breaking Medicine News(10 mins):Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... ... Locally, , ... WA (PRWEB) July 2, 2010 -- Bill the Butcher Inc. opened a neighborhood butcher ... executive officer., , ,Located at 3800 34th Ave West in Seattle,s Magnolia neighborhood, the ...
... patients with Hodgkin lymphoma (HL) and a history of heart ... after completing treatment, according to research published online today in ... Hematology. HL is a form of cancer of arising in ... the disease in 2009, according to the American Cancer Society. ...
... at Karolinska Institutet recommends a new routine for protection ... for feeding directly through the abdominal wall, is surgically ... simpler and cheaper than the one used today. The ... has been clinically tested on over 200 patients at ...
... Register now for ... of women, at the Mariandale Retreat Center -- right outside of NYC, which will be held ... workshops, room and board, is only $350 until July 9, 2010. , ... New York, NY (PRWEB) July 2, 2010 -- Need to get ...
... ... is pleased to announce the Grand Opening of their newly expanded pain treatment center in ... ... are located at 638 West Duarte Road, Suite 18, Arcadia, California 91007. The Los Angeles ...
... ... , ... 1, 2010-- Aromatherapy isn’t new to the field of natural health. Ancient Egyptians were the ... the Romans to modern day, essential oils have been part of a holistic approach to ...
Cached Medicine News:Health News:In Time for July 4th Grilling, Bill the Butcher Opens 5th Butcher Shop 2Health News:Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization 2Health News:Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach 2Health News:Relax, Release and Rejuvenate at Upcoming Women's Retreat 2Health News:Relax, Release and Rejuvenate at Upcoming Women's Retreat 3Health News:Advanced Pain Institute Opens Expanded Los Angeles Area Pain Management Center 2Health News:Certified Organic Aromatherapy Oils Available from Swanson Health Products 2
... An APTT-based kit for the screening of ... specificity of the test for the factor ... sample plasma with an excess of V-DEF ... possible to discriminate between heterozygous and homozygous ...
Inquire...
Inquire...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
Medicine Products: